Drolet Stock Notes on IMV Inc.: A clinical stage company developing a first-in-class T cell targeted immune therapy for cancer

Mario Drolet, President of MI3 Communications Financières Inc. (MI3), released his Drolet Stock Notes on IMV Inc. (NASDAQ: IMV | TSX: IMV) on January 31, 2022, for exclusive distribution on InvestorIntel. Highlights include:

  • IMV Inc. is a clinical-stage pharmaceutical company that has the potential to make history by developing a first-in-class effective T cell-targeted immune therapy for cancer.
  • The DPX™ Delivery Platform Offers Multiple Oncology and Non-Oncology Therapeutic Possibilities.
  • In 2021, maveropepimut-S (DPX-Survivac) is evaluated in phase 2 clinical studies in several cancer indications, including in combination with Merck’s Keytruda®.
  • Rebounding from the low. Flirting with oversold territory. New CEO aboard!
  • IMV Inc. Support: S2; $1.37      S1; $ 1.40      Resistance:   R1; $ 1.45   R2; $1.50

About IMV Inc.

IMV Inc. is a clinical-stage immuno-oncology company advancing a portfolio of therapies based on the Company’s immune-educating platform: the DPX™ technology. Through a differentiated mechanism of action, the DPX platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. IMV’s lead candidate, maveropepimut-S (MVP-S), delivers antigenic peptides of survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers. MVP-S treatment has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. MVP-S is currently being evaluated in clinical trials for hematologic and solid cancers, including Diffuse Large B Cell Lymphoma (DLBCL) as well as ovarian, bladder and breast cancers. IMV is also developing a second immunotherapy leveraging the DPX immune delivery platform, DPX-SurMAGE. This dual-targeted immunotherapy combines antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously. A Phase 1 clinical trial in bladder cancer will open early 2022.


Disclaimer: This MI3 Technical Note produced by MI³ Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI³ Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this report.